Avan Armaghani, MD, reviews three key topics in the management of hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer to be explored at this year’s ...

PHILADELPHIA and VANCOUVER, British Columbia, Dec. 10, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (BCTX) (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or ...

SABCS 2025 will address key topics such as alcohol's impact on breast cancer, lobular breast cancer, and breast cancer in young women. The symposium will present new research, including significant ...

Data include findings generated using the RaDaR 1.0 assay to assess molecular residual disease and recurrence risk in early breast cancer NeoGenomics will present new data from the SURVIVE HERoes ...

HOUSTON, Feb. 16, 2026 /PRNewswire/ -- New data presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) from the NRG/NSABP B-42 trial demonstrated that the Endocrine Activity Index (EAI) ...

BriaCell (BCTX) Therapeutics presents positive Phase 2 survival, and Phase 3 biomarker data across three clinical posters at the 2025 San Antonio Breast Cancer Symposium, SABCS, taking place December ...

Editor's note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

New York, NY (December 8, 2025) – Researchers and clinicians from the Icahn School of Medicine at Mount Sinai will present new discoveries in breast cancer biology, treatment, and real-world patient ...

PHILADELPHIA and VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage ...

PHILADELPHIA and VANCOUVER, British Columbia, Dec. 10, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage ...